Theravance Biopharma (NASDAQ:TBPH) Cut to Buy at Wall Street Zen
by Amy Steele · The Cerbat GemWall Street Zen cut shares of Theravance Biopharma (NASDAQ:TBPH – Free Report) from a strong-buy rating to a buy rating in a research note published on Monday morning.
A number of other research analysts have also recently weighed in on the company. Weiss Ratings raised Theravance Biopharma from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, March 24th. Zacks Research raised Theravance Biopharma from a “hold” rating to a “strong-buy” rating in a research note on Thursday, March 19th. BTIG Research reissued a “buy” rating and set a $21.00 target price on shares of Theravance Biopharma in a research note on Friday, March 20th. HC Wainwright lifted their target price on Theravance Biopharma from $20.00 to $27.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Finally, Oppenheimer downgraded Theravance Biopharma from an “outperform” rating to a “market perform” rating in a research note on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.83.
Read Our Latest Report on Theravance Biopharma
Theravance Biopharma Stock Up 0.2%
TBPH stock opened at $16.60 on Monday. Theravance Biopharma has a twelve month low of $8.09 and a twelve month high of $21.03. The stock has a market cap of $854.73 million, a P/E ratio of 8.18 and a beta of 0.17. The business’s 50-day moving average price is $16.86 and its 200-day moving average price is $17.02.
Insider Transactions at Theravance Biopharma
In related news, SVP Rhonda Farnum sold 31,067 shares of Theravance Biopharma stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president owned 232,699 shares of the company’s stock, valued at approximately $3,248,478.04. This trade represents a 11.78% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 6.90% of the company’s stock.
Institutional Trading of Theravance Biopharma
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quarry LP bought a new stake in Theravance Biopharma in the 3rd quarter worth approximately $26,000. Caitong International Asset Management Co. Ltd increased its stake in Theravance Biopharma by 107.4% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 2,725 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 1,411 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in Theravance Biopharma by 26.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,462 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 515 shares during the last quarter. Tower Research Capital LLC TRC increased its stake in Theravance Biopharma by 18.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,013 shares of the biopharmaceutical company’s stock worth $55,000 after acquiring an additional 781 shares during the last quarter. Finally, CIBC Private Wealth Group LLC increased its stake in Theravance Biopharma by 20,269.6% in the 3rd quarter. CIBC Private Wealth Group LLC now owns 4,685 shares of the biopharmaceutical company’s stock worth $68,000 after acquiring an additional 4,662 shares during the last quarter. Institutional investors own 99.10% of the company’s stock.
About Theravance Biopharma
Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.